AstraZenca Code of Ethics
Carrie "Shellie" Cobbs
Ethics: Health Care and Social Responsibility
June 09, 2013
AstraZenca Code of Ethics
Many of us have heard of AstraZenca on television commercials but have not really paid too much attention. A few brand named medicines are Crestor, for cardiac issues, and Nexium, for gastrointestinal issues, Atenolol, Pulmicort, Seroquel, Symbicort, and Zestril. AstraZeneca is a global company that is regulated by every country it works in. Maintaining a high ethical platform for the company and the employees is vital to the continued success of AstraZeneca.
Goals set by AstraZeneca
AstraZeneca maintains a detailed Code of Conduct for the global organization it runs. Employees are held to a high standard of training and are required to complete yearly re-training on the company’s code. New employees are required to complete training within 30 days of employment. This annual training reestablishes a connection with the company’s goals and their work ethic with the employees so that a common knowledge is understood. AstraZeneca has many goals they strive to achieve and without an understanding of these goals presented to the employees then the code of conduct would not be able to be upheld. Research and Development Ethics
AstraZeneca is constantly trying to develop new medicines. These medicines must be tested and researched before being put on the market for human use. National and international laws dictate how to record information and data collected and this is one of the goals set forth by AstraZeneca. In order to be in compliance AstraZeneca must follow guidelines for recording data and they must maintain transparency when reporting the collected information. Failure to do so results in fines, loss of funding and grants, and possibly being shut down. Interactions with Health Care Professionals and Organizations
In the past pharmaceutical companies were allowed to court...
References: Code of Conduct. (2013). Retrieved June 9, 2013, from http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DEnglish.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285646174592&ssbinary=true
Duke, E. M. (2003). OIG Compliance Program Guidance for Pharmaceutical Manufactuers. Retrieved from http://oig.hhs.gov/authorities/docs/03/050503FRCPGPharmac.pdf
Please join StudyMode to read the full document